Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06511050Phase 1Recruiting

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Role: collaborator

NCT06511063Phase 2Recruiting

Antiviral Clinical Trial for Long Covid-19

Role: collaborator

NCT05877508Phase 2Active Not Recruiting

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Role: collaborator

NCT06960928Phase 3Recruiting

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

Role: collaborator

All 4 trials loaded